Zhaoke Ophthalmology Ltd
HKEX:6622
Net Margin
Zhaoke Ophthalmology Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
|
Zhaoke Ophthalmology Ltd
HKEX:6622
|
1.5B HKD |
-343%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
751.6B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
377.4B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
204.3B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
188.5B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
162B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
209.7B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
184.8B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.8B USD |
13%
|
Zhaoke Ophthalmology Ltd
Glance View
Zhaoke Ophthalmology Ltd. operates as holding company with interest in providing ophthalmic pharmaceuticals. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2021-04-29. The Company’s products include innovative drugs and generic drugs. The firm ‘s products are mainly applied in five ophthalmic indications, including dry eye disease (DED), wet age-related macular degeneration (wAMD), diabetic macular edema (DME), myopia and glaucoma.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Zhaoke Ophthalmology Ltd's most recent financial statements, the company has Net Margin of -342.6%.
You don't have any saved screeners yet